Jefferies on Thursday launched its coverage of oncology-focused biotech Verastem (NASDAQ:VSTM) with a Buy rating and $15 per share target, citing a potential FDA nod for its ovarian cancer drug combo ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Chemotherapy regimens chosen by the ChemoID assay dramatically increased ORR in patients with platinum-resistant ovarian ...

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

In a study co-led by the University of Maryland School of Medicine (UMSOM), researchers have identified a “master regulator” ...

Corcept Therapeutics (NasdaqCM:CORT) recently announced successful results from its ROSELLA trial for relacorilant plus nab-paclitaxel, indicating a notable positive stride in treatment for ...

The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ...

(Reuters) -Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type of ovarian cancer in a late-stage trial. Shares of Corcept ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy ...